Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

2. HDS Pulmonary > Bacterial Pneumonia > Flashcards

Bacterial Pneumonia Flashcards

1
Q

Respiratory Immune Defenses

A
  • Mucus
  • sIgA
  • Lysozyme
  • Lactoferrin
  • Mucocilliary escalator
  • Alveolar MΦ
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Respiratory

Immune Compromise

A
  • Preceding URT infection
  • Pulmonary disease
  • Chemical or mechanical injury
  • Generalized host immunocompromise
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

LRT Infection

Classification

A
  • Bronchitis ⇒ inflammation of bronchial tree
    • Often preceded by URT infection
    • Can be part of clinical presentation of influenza, rubella, pertussis, Scarlet fever
  • Pneumonia ⇒ inflammation of lung parenchyma
    • Due to many bacteria, viruses, and fungi
    • Typical ⇒ acute
    • Atypical ⇒ subacute
    • Chronic PNA ⇒ takes weeks to months to develop sx
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Community Acquired PNA

A

PNA occuring in usually healthy persons not confined to an institution.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Nosocomial / Hospital Acquired PNA

A

PNA arising while a patient is hospitalized or living in an institution such as a nursing home.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Lobar PNA

A

Pulmonary consolidation demarcated by border or segment or lobe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Bronchopneumonia

A

Patchy consolidation around the larger airways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Interstitial PNA

A

Fine areas of interstitial infiltration in the lung fields

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Aspiration PNA

A

Follows aspiration of oral or gastric contents leading to damage caused by chemical or mechanical insult.

Bacterial damage may be caused by normal flora such as oral Strep or GI bacteria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Typical PNA

Differential Dx

A
  1. Strep pneumoniae
    • # 1 cause of CAP, nosocomial
    • 500k cases/yr in the US
  2. Staph aureus
    • Secondary pathogen
    • Nosocomial
    • MRSA vs MSSA
  3. Haemophilus influenzae​
    • Secondary pathogen
  4. Klebsiella pneumoniae
    • ​Older, alcoholic, nosocomial
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

S. pneumoniae

Pathologies

A
  • CAP ⇒ most common cause
  • Meningitis ⇒ leading cause in adults
    • May follow PNA or infection @ other site, or w/ no apparent preceding infection
    • All ages affected, most common bacterial cause in advanced ages
  • Otitis media ⇒ leading cause in children
  • Sinusitis
  • Bacteremia ⇒ occurs in 25% of pts w/ infection
    • Leads to endocarditis, arthritis, peritonitis, septic shock
    • Functional spleen is critical
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

S. pneumoniae

Epidemiology & Transmission

A
  • Transmission:
    • Endogenous usually
    • Transmitted via respiratory secretions
    • Accompanied by pre-disposing factors
  • Epidemiology:
    • Infects humans, no reservoir
    • ​20-40% are carriers in NP
    • Incidence greatest < 6 y/o and > 60 y/o
    • 1 mil deaths worldwide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pneumococcal PNA

Risk Factors

A
  • Alcoholism
  • DM
  • CKD
  • Some malignancies
  • Bronchial injury d/t smoking or air pollution
  • Respiratory dysfunction 2/2 EtOH, narcotics, anesthesia, trauma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

S. pneumoniae

Morphology & Characteristics

A

> 80 serotypes based on capsular polysacc.

In US, 23 serotypes cause > 90% of PNA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

S. pneumoniae

Virulence Factors

A
  • Polysaccharide capsule ⇒ major factor
    • Anti-phagocytic
    • Strains w/ large capsules more virulent
    • Loss ⇒ avirulent
  • IgA protease
    • Aids establishment of infection
  • Pneumolysin
    • Toxin w/ pore-forming action
    • Injures cilia and endothelial cells ⇒ aids spread
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

S. pneumoniae

Pathogenesis

A
  • Aspiration of respiratory secretions containing pneumococci into alveoli
  • Multiplication of organisms
  • Massive inflammatory response, mostly PMNs
  • Edema and accumulation of pus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Acute Pneumococcal PNA

Presentation

A
  • Abrupt onset shaking chills, high fever, SOB
  • Significant productive cough w/ pink-rusty sputum
    • Sputum: abundant inflammatory cells, single organism predominant, gram ⊕ diplococci
  • Pleuritic chest pain on breathing
  • Chest sounds
    • Dec. breath sounds
    • Dullness on percussion
    • Rales or crackles
  • CXR ⇒ Lobar consolidation
    • PMN exudate, clotting of alveolar fluid, ± complete consolidation of one lobe
  • Leukocytosis with mostly PMNs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

S. pneumoniae

Diagnosis

A
  • Smear ⇒ gram ⊕ cocci
  • Culture ⇒ blood agar or blood culture
  • Optochin sensitive
  • Detection of capsular Ag
    • Latex agglutination test
    • Quellung reaction
      • Ab to organisms in pure culture or clinical material
      • Causes capsule to swell
      • Can be used for typing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

S. pneumoniae

Immunity

A

Immunity strain specific & dependent on capsular type.

  • Innate ⇒ important early
    • Phagocytosis by PMNs & MΦ
    • Alternative complement pathway ⇒ opsonization by C3b
    • Both are inefficient d/t polysacc. capsule
  • Acquired ⇒ needed to clear
    • Anti-capsular IgG ⇒ opsonization & effective phagocytosis
    • Classic complement activation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

S. pneumoniae

Treatment

A

50% are PCN resistant

Fluoroquinolones or Vancomycin for serious disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

S. pneumoniae

Prevention

A
  • 1st gen vaccine (Pneumovax 23)
    • Capsular polysacc. from 23 most common serotypes
    • Rec. for high risk pts
  • Conjugate vaccine (Prevnar 13)
    • 13 invasive serotypes polysacc. + CRM proteins
    • Given to infants as part of routine vaccinations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Klebsiella pneumoniae

Characteristics

A

Normal flora of oral and GI tract.

Needs to be plated on special media.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Klebsiella pneumoniae

Virulence Factors

A
  1. Thick mucoid capsule
  2. Endotoxin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Klebsiella pneumoniae

Epidemiology & Transmission

A
  • Opportunistic pathogen
  • Endogenous transmission
    • Aspiration or via URT
  • CAP and HAP
  • Affects older pts w/ risk factors
    • Alcoholism, smoking, underlying lung disease, nosocomial
  • ♂ > ♀
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Klebsiella pneumoniae

Pathogenesis & Clinical Presentation

A

Presents as a typical pneumonia.

Necrotizing w/ production of thick, viscous, bloody sputum ⇒ “currant jelly”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Klebsiella pneumonia

Treatment

A
  • Inc. resistance to multiple classes of abx
    • CRE ⇒ carbepenem resistant Enterobacteriaceae
      • Largely consists of Klebsiella
      • Responsible for multiple outbreaks
  • Choices guided by susceptibility
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Pseudomonas aeruginosa

Overview

A
  • Ubiquitous ⇒ found in soil, water, vegetation
    • Prefers moist reservoirs
  • Very hardy
  • Opportunistic pathogens
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Pseudomonas aeruginosa

Morphology and Characteristics

A
  • Gram-⊖ rod
  • Aerobic
  • Motile
  • Oxidase ⊕
    • Aids in differentiation from other enterics
  • Pyocyanin, pyoverdin
    • Blue-green pigment on agar media
29
Q

P. aeruginosa

Transmission & Epidemiology

A
  • Found everywhere
  • Inhabit the hospital environment
    • Food, flowers, sinks, respiratory therapy and dialysis equipment, disinfectants
  • Hospital personnel ⇒ high rates of carriage
  • Transfer to hospitalized pts
30
Q

P. aeruginosa

Virulence Factors

A
  • Capsular slime ⇒ mucoid exo-polysacc, alginate
    • Under complex regulation
    • Forms a biofilm under certain conditions
  • Exotoxin A
    • ADP ribosylation of EF-2 ⇒ ⊗ protein synthesis
      • Similar to mech. to DT but less potent
    • Best correlated w/ virulence
    • Ab to exotoxin A are protective
  • Endotoxin (LPS)
    • Sepsis
  • Enterotoxin
  • Proteolytic enzymes
  • Leukocidin
  • Hemolysin
  • Pili
31
Q

P. aeruginosa

Pathologies

A

Can cause infection of almost any tissue:

  • PNA
  • Sepsis
  • Skin and soft tissue infections
  • UTI
  • Endocarditis
32
Q

P. aeruginosa

Risk Factors

A
  • Broad spectrum antimicrobial therapy
  • Mechanical ventilation
  • CF pts ⇒ PNA
  • Burn pts ⇒ sepsis
33
Q

P. aeruginosa

Pathogenesis

A
  • Usually requires ∆ in host defense
  • Causes ~ 15% of all nosocomial infections
  • Asymptomatic infection to diffuse b/l bronchopneumonia w/ microabscess formation
  • May remain localized @ site of injury or infection
  • Bacteremia common ⇒ dissemination & sepsis
  • Can cause abscess formation and lung destruction
34
Q

P. aeruginosa & Cystic Fibrosis

A
  • CF and ventilary assistance ⇒ high risk for PNA
  • Most CF pts have chronic respiratory tract infection by mucoid strains of P. aeruginosa
    • Starts ~ 15-18 y/o
  • Can cause severe necrotizing bronchopneumonia
35
Q

P. aeruginosa

Treatment

A
  • Highly resistant to most abx
    • Mediated by multiple mechs
      • Inherent and acquired
      • Mutation of porin proteins
  • Combo therapy required
    • Newer β-lactams & aminoglycosides
  • Therapy based on drug susceptibility tests
36
Q

P. aeruginosa

Prevention

A
  • Eliminating from hospital setting very difficulty
  • Preventative measures
    • Hand washing
    • Air filtration
    • Proper disinfection of equipment
    • Effective sanitation
    • Avoid inappropriate use of broad spectrum abx
  • More cases ass. w/ contaminated hot tubs and spas
37
Q

Primary Atypical Pneumonia

(PAP)

A

“Walking pneumonia”

  • Insidious onset ⇒ malaise, headache, low fever
  • Non or minimally productive cough
    • Sputum: PMNs, low/no pathogens vs difficulty staining
  • Chest sounds ⇒ scattered crepitations or unremarkable
  • CXR ⇒ patchy infiltrate mostly in large airways, little consolidation
  • Normal WBC count
38
Q

Primary Atypical Pneumonia

Etiologies

A

Syndrome of multiple etiologies.

  • Mycoplasma pneumoniae
  • Chlamydophila pneumoniae
  • Legionella pneumophila
  • Chlamydia psittaci
  • Coxiella burnetii
  • Adenovirus
  • Influenza
39
Q

Mycoplasma pneumoniae

Overview

A
  • Causes 10-15% of all PNA
    • # 1 cause of PAP @ 20-25%
  • Common cause of tracheobronchitis
  • Pharyngitis
40
Q

M. pneumoniae

Morphology

A
  • Smallest free-living reproductive unit known
  • Highly pleomorphic
  • No cell wall ⇒ stains very poorly
  • Triple layered membrane
    • High [sterols]
      • Required for growth
41
Q

M. pneumoniae

Transmission and Epidemiology

A
  • Respiratory transmission ⇒ aerosol droplets
  • 2-3 week incubation
  • Occurs primarily in pre-adolescent and adolescent children
42
Q

M. pneumoniae

Pathogenesis

A
  • Virulence
    • Attaches via P1 adhesin
  • Extracellular
    • Damages epithelium
    • ⊗ Ciliary action
  • Secretes ROI
    • Damages bronchial tissue
  • Induces acute inflammation
    • Causes most of the damage
43
Q

M. pneumoniae

Clinical Course

A
  • 2-3 week incubation period
  • Sx lasts 1-4 weeks ⇒ “walking PNA”
  • Self-limiting diseae
  • Convalescence is slow
  • Transmission continues during and after clinical recovery
  • Sickle cell and other immunocompromised pts ⇒ may have fulminant disease
44
Q

M. pneumoniae

Diagnosis

A
  • Culture from sputum ⇒ usually impractical
  • Grow on complex media
    • Egg based media supplemented w/ lipoprotein, sterols, 5% CO2
    • “Fried egg” colonies grow after 3-10 days
  • Cold agglutinins ⇒ IgM to mycoplasma glycolipids that cross-react w/ hRBCs
    • Agglutination at low temps
    • Single titer > 64 supports Dx
    • ⊕ in ½ - ⅔ of symptomatic pts
    • False ⊕ ⇒ adenovirus, mononucleosis
    • Non-specific assay
  • Complement fixation ⇒ poor sensitivity
    • Rise in titer during infection
    • High incidence of seropositives in nl population
45
Q

M. pneumoniae

Treatment

A

Tetracycline and erythromycin ⇒ effective against all causes of bacterial atypical PNA

Mycoplasmas ⇒ resistant to cell wall inhibitors

46
Q

Chlamydia

Characteristics

A
  • Small gram ⊖ organisms
  • Obligate intracellular pathogens
  • Unique life cycle
  • Causes respiratory infections, STI, trachoma (leads to blindness)
47
Q

Chlamydia

Development Cycle

A

Elementary body (EB) ⇒ transmissible form

Reticulate body (RB) ⇒ replicative form

Site of intracellular binary fission called an inclusion body, can be stained for ID.

48
Q

Chlamydophila pneumoniae

Characteristics

A
  • Causes PAP similar to M. pneumoniae
  • Transmitted person to person
  • Causes up to 20% of CAP in young adults
  • Implicated in development of asthma and exacerbations
    • Ass. w/ inadequate or delayed clearance
49
Q

Chlamydophila pneumoniae

Clinical Manifestations

A
  • Asymptomatic infections or mild illness
  • PAP
  • Pharyngitis
  • Sinusitis
  • Otitis media ⇒ 50% of adults are seropositive
  • Asthma development
50
Q

Chlamydophila pneumoniae

Diagnosis, Treatment, Immunity

A

Dx: IgM titer of ≥ 15 or IgG titer ≥ 512

Treatment: tetracycline or erythromycin

Immunity: cell-mediated (Th1) mechanism

51
Q

C. pneumoniae & Atherosclerosis

A

Hypothesis:

  • High titers of Ab in adults w/ CAD
  • Organism cultured from atherosclerotic lesions
  • Animal models support inflammatory events
  • Even mild or asymptomatic infections can cause chronic inflammatory response that may exacerbate atherogenesis
52
Q

Legionnaire’s Disease

A

Caused by Legionella pneumophila

First appeared in 1976 @ American Legion Convention in Philadelphia

Causes 10-15% of all pneumonias (CAP & HAP)

53
Q

Legionella

Characteristics

A
  • Prefers warm water
    • Lakes, streams, coastal ocean
  • Small gram ⊖ coccobacilli
  • Facultative intracellular pathogen
  • Replicates within amoebas ⇒ forms biofilms
    • Infected ameobae can encyst when environment unfavorable
  • Free living bacteria enter low metabolic state ⇒ forms biofilms
54
Q

Legionella

Transmission

A
  • Infectious aerosols
    • No person to person transmission
  • Relatively chlorine resistant
  • Grow at high temps 46°C
  • Nosocomial pathogen
    • Respiratory therapy equipment, ventilators
    • Water cooling towers
55
Q

Legionella

Pathogenesis

A
  • Asymptomatic disease ⇒ common
  • Clinical disease ⇒ usually requires underlying factor
    • Advanced age
    • Smoking
    • Chronic pulmonary disease
    • Immunosuppression
    • DM
  • Clinical disease depends on size of inoclum & host status
  • Nosocomial ⇒ outbreaks common in nursing homes
56
Q

Legionella

Virulence Factors

A
  • Facultative intracellular pathogen, replicates inside Mφ
    • ⊗ Phagosome-lysosome fusion
    • ⊗ Oxidative and non-oxidative killing
  • Hijacks nutrients from cells by coating w/ RER
57
Q

Legionnaires Disease

Clinical Presentation

A
  • Fever, myalgias, HA, non-productive cough
  • Develop into bronchitis, bronchiolitis, and confluent PNA
    • Productive cough w/ watery sputum, CP
    • Multi-lobe involvement of the lungs
  • GI symptoms ⇒ 50% of cases
    • N/V/D, abd pain
  • Systemic infection
58
Q

Legionella

Diagnosis

A
  • Gram ⊖ coccobacilli
    • Poorly staining
  • Culture ⇒ requires L-cysteine
    • Called buffered charcoal yeast extract
    • Slow growth in 3-14 days
    • Greyish-white colonies
  • EIA of urine ⇒ Group 1 specific LPS antigen
    • Serogroup 1 causes 80-90% CAP, 50% HAP
59
Q

Legionella

Treatment

A

Macrolides or Quinolones

⇒ Must penetrate infected cells

⇒ Mortality 15-30%

60
Q

Legionella

Prevention

A

Monitoring water system

  • Hyper-chlorination of water
  • Treatment w/ copper or silver ions
  • Cycle of superheating (70°C) and flushing
  • Maintenance of hot water temp > 50°C
61
Q

Pontiac Fever

A

Also caused by Legionella pneumophila

  • Mild flu-like URT infection
  • Short duration
  • Self-limiting
  • High attack rate
  • Healthy as well as high risk individuals
62
Q

Zoonotic

Atypical Pneumonia

A

Animal pathogens that infect humans:

Chlamydia psittaci

Coxiella burnetii

63
Q

Chlamydia psittaci

A
  • Infects parrots, parakeets, and other birds ⇒ psittacosis
  • Can also infect chickens ⇒ ornithosis
  • Transmission via respiratory secretions of infected birds
    • Living or dead
    • Poultry processing at high risk
  • Person to person transmission rare
  • Dx ⇒ serology
64
Q

Psittacosis / Ornithosis

A
  • 25-50 cases/yr
  • Mild infections
    • Malaise, fever, anorexia, ST, HA, photophobia, non-productive cough
    • May include CNS or GI sx
  • Ranges from self-limiting to severe
    • Elderly have significant mortality
65
Q

Coxiella burnetii

A
  • A Rickesttsial agent
    • Includes Rickettsiae, Ehrlichia, Orientia, and Coxiella
    • Obligate intracellular gram ⊖ organisms
    • Infects ticks, lice, fleas, mites, chigggers, wild and domestic mammals
  • Shed in milk, urine, and feces
    • Can get infected from airborne particles formed from urine and feces
  • Resistant to heat and dessication
  • Causes Q fever
66
Q

Coxiella burnetii

Transmission

A
  • Contact w/ dust in sheep or cattle sheds
  • Ingestion of contaminated milk
  • Handling contaminated hides or wool
  • Fetal or placental tissue during birthing
  • Occupational hazard for tanners, sheep herders and shearers, cattle farmers
  • No person-to-person transmission
67
Q

Q Fever

A
  • Chills, fever, HA, myalgias, malaise
  • Pneumonia in 50% of pts
  • Hepatitis, endocarditis
  • Clinical syndrome lasts 1-4 weeks
  • Usually self-limiting w/ gradual resolution
68
Q

Community Acquired PNA

Etiology Summary

A

2. HDS Pulmonary (28 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions